MSCT findings and histological feature correlations of pancreatic metastases from clear renal cell carcinoma.
The growing use of MSCT in the follow-up of oncologic patients allows early detection of very small pancreatic lesions and particularly of secondary neoplasms.
We present three cases of pancreatic metastases from clear renal carcinoma confirmed with 64-row MSCT and with histological confirmation of primary RCC and related metastases.
In larger lesions, intravascular contrast administration reveals the differentiation between hypercellular periphery and internal hypodense portions. The hypercellular regions are less vacularized (Figures 1 and 2).
Smaller lesions, seen by more enhancement on arterial phase, were visible as a small spot of extraductal iodine hyperimpregnation and showed a persistence of iodine staining on later scans. Histologically, these demonstrate a prevalence of microvessels and hypercellularity with reduced interstitial anarchy (Figures 3, 4, 5).
It’s probable that the use of recent MSCT scanners, with their superior spatial and temporal resolution, reveals small pancreatic lesions that formerly were missed. In these patients subsequent surgical and medical treatment results in high survival, but makes radiological follow-up extremely important.
Dr. M. Marasà is with the Institute of Radiology at the University of Palermo in Italy; Dr. Dav ì is with the Operative Unit of Vascular and Interventional Radiology at ARNAS-Civico Hospita in Palermo; and Dr. S. Marasà is with the Institute of Pathologic Anatomy at the University of Palermo.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.